Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2022 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference

PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
March 17, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates

IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission Entered into a strategic...
February 09, 2022 16:05 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
January 10, 2022 06:59 ET | Source: Century Therapeutics, Inc.

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

- Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development - - First...
January 04, 2022 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
December 17, 2021 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Added to the NASDAQ Biotechnology Index

PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
December 16, 2021 06:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of...
November 22, 2021 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
November 10, 2021 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the...
November 04, 2021 09:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update

PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...